# Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

> **NCT01278615** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Recurrent Adult Diffuse Large Cell Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT01278615
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2014-02
- **Final completion:** 2014-05
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Closed Prematurely.
- **Last updated:** 2016-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01278615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01278615, "Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01278615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*